Tyrosine kinase 3D structures
From Proteopedia
(Difference between revisions)
Line 5: | Line 5: | ||
*'''NON-RECEPTOR TYROSINE KINASES - nRTK''' | *'''NON-RECEPTOR TYROSINE KINASES - nRTK''' | ||
+ | |||
+ | *'''Fyn tyrosine kinase''' (Domains: SH3 80-141; SH2 142-247; kinase 260-537) | ||
+ | |||
+ | **[[1shf]], [[3ua6]] – hTK Fyn SH3 domain – human<br /> | ||
+ | **[[3h0f]], [[3h0h]], [[3h0i]], [[3cqt]], [[6ipz]], [[6ipy]] - hTK Fyn SH3 domain (mutant)<br /> | ||
+ | **[[1zbj]], [[1nyg]], [[1nyf]] - hTK Fyn SH3 domain – NMR<br /> | ||
+ | **[[1g83]] - hTK Fyn SH2+SH3 domains (mutant)<br /> | ||
+ | **[[4u17]] – hTK Fyn SH2 domain<br /> | ||
+ | **[[2mrj]], [[2mqi]] – hTK Fyn SH2 domain - NMR<br /> | ||
+ | **[[6edf]] - hTK Fyn residues 1-77<br /> | ||
+ | **[[3uf4]] – mTK Fyn SH3-SH2 domain – mouse<br /> | ||
+ | **[[3uf4]] - mTK Fyn SH2+SH3 domains<br /> | ||
+ | **[[2l2p]], [[2lp5]] - cTK Fyn SH3 domain (mutant) - chicken - NMR<br /> | ||
+ | |||
+ | *Fyn complex | ||
+ | |||
+ | **[[1fyn]], [[4znx]] - hTK Fyn SH3 domain + peptide<br /> | ||
+ | **[[1nyf]], [[1nyg]], [[1a0n]], [[1azg]] - hTK Fyn SH3 domain + peptide – NMR<br /> | ||
+ | **[[5zau]] - hTK Fyn SH3 domain + monobody binder – NMR<br /> | ||
+ | **[[1efn]], [[1avz]] - hTK Fyn SH3 domain + HIV Nef protein<br /> | ||
+ | **[[4d8d]], [[7d7s]] - hTK Fyn SH3 domain (mutant) + HIV Nef protein<br /> | ||
+ | **[[1m27]] - hTK Fyn SH3 domain + SH2 domain protein 1A + SLAM peptide<br /> | ||
+ | **[[4d8d]], [[1efn]] - hTK Fyn SH3 domain (mutant) + HIV Nef protein<br /> | ||
+ | **[[3ua7]] – hTK Fyn SH3 domain + hepatitis virus peptide<br /> | ||
+ | **[[4eik]] - hTK Fyn SH3 domain + VSL12 peptide<br /> | ||
+ | **[[4u1p]] - hTK Fyn SH2 domain + phosphopeptide<BR /> | ||
+ | **[[1aot]], [[1aou]], [[2mrk]] - hTK Fyn SH2 domain + phosphopeptide - NMR<BR /> | ||
+ | **[[2dq7]] – hTK kinase domain + staurosporine<br /> | ||
*'''Abelson tyrosine kinase''' | *'''Abelson tyrosine kinase''' | ||
Line 85: | Line 113: | ||
**[[2kk1]] – hTK C terminal – NMR<BR /> | **[[2kk1]] – hTK C terminal – NMR<BR /> | ||
- | |||
- | *'''Ack1 tyrosine kinase''' or '''activated cdc42 kinase 1''' | ||
- | |||
- | **[[1u46]], [[4hzr]] - hTK Ack1 kinase domain <br /> | ||
- | **[[4hzs]] - hTK Ack1 kinase+SH3 domains <br /> | ||
- | **[[1u54]] - hTK Ack1 kinase domain + AMPPCP <br /> | ||
- | **[[1u4d]], [[3eqp]], [[3eqr]], [[4ewh]], [[4id7]], [[5zxb]] - hTK Ack1 kinase domain + inhibitor<br /> | ||
*'''Anaplastic lymphoma kinase (Alk)''' or '''Alk tyrosine kinase receptor''' | *'''Anaplastic lymphoma kinase (Alk)''' or '''Alk tyrosine kinase receptor''' | ||
Line 101: | Line 122: | ||
**[[2xp2]], [[6mx8]], [[5fto]], [[5ftq]] - hTK kinase domain + cancer drug<br /> | **[[2xp2]], [[6mx8]], [[5fto]], [[5ftq]] - hTK kinase domain + cancer drug<br /> | ||
**[[2yfx]], [[4anq]], [[4ans]], [[5aaa]], [[5aab]], [[5aac]], [[5a9u]], [[5aa8]], [[5aa9]] - hTK kinase domain (mutant) + cancer drug<br /> | **[[2yfx]], [[4anq]], [[4ans]], [[5aaa]], [[5aab]], [[5aac]], [[5a9u]], [[5aa8]], [[5aa9]] - hTK kinase domain (mutant) + cancer drug<br /> | ||
- | |||
- | *'''CapAB tyrosine kinase''' | ||
- | |||
- | **[[3bfv]] - SaTK CapA1/CapB2 – ''Staphylococcus aureus'' <br /> | ||
- | **[[2ved]] - SaTK CapA1/CapB2 + Mg + ADP | ||
*'''Csk tyrosine kinase''' or '''C-terminal Src kinase''' | *'''Csk tyrosine kinase''' or '''C-terminal Src kinase''' | ||
Line 117: | Line 133: | ||
**[[3d7t]], [[3d7u]] - hTK Csk kinase domain (mutant) + C-Src<br /> | **[[3d7t]], [[3d7u]] - hTK Csk kinase domain (mutant) + C-Src<br /> | ||
**[[1k9a]] - TK Csk C terminal - rat<br /> | **[[1k9a]] - TK Csk C terminal - rat<br /> | ||
- | |||
- | *'''Etk tyrosine kinase''' | ||
- | |||
- | **[[3cio]] - EcTK Etk kinase domain – ''Escherichia coli''<br /> | ||
- | |||
- | *'''Fer tyrosine kinase''' | ||
- | |||
- | **[[2kk6]] - hTK Fer SH2 domain – NMR<BR /> | ||
- | **[[6kc4]] - hTK Fer SH2 domain + phosphopeptide<BR /> | ||
- | |||
- | *'''Fes/Fps tyrosine kinase''' | ||
- | |||
- | **[[1wqu]], [[2dcr]] - hTK Fes SH2 domain - NMR<br /> | ||
- | **[[3bkb]] - hTK Fes SH2+kinase domain - NMR<br /> | ||
- | **[[4dyl]] - hTK Fes F-Bar domain <br /> | ||
- | **[[3cbl]] - hTK Fes SH2+kinase domain + peptide<br /> | ||
- | **[[3cd3]] - hTK Fes SH2+kinase domain + peptide + staurosporine<br /> | ||
- | **[[4e93]], [[6jmf]] - hTK TFes + inhibitor<br /> | ||
- | |||
- | *'''Fyn tyrosine kinase''' (Domains: SH3 80-141; SH2 142-247; kinase 260-537) | ||
- | |||
- | **[[1shf]], [[3ua6]] – hTK Fyn SH3 domain – human<br /> | ||
- | **[[3h0f]], [[3h0h]], [[3h0i]], [[3cqt]], [[6ipz]], [[6ipy]] - hTK Fyn SH3 domain (mutant)<br /> | ||
- | **[[1zbj]], [[1nyg]], [[1nyf]] - hTK Fyn SH3 domain – NMR<br /> | ||
- | **[[1g83]] - hTK Fyn SH2+SH3 domains (mutant)<br /> | ||
- | **[[4u17]] – hTK Fyn SH2 domain<br /> | ||
- | **[[2mrj]], [[2mqi]] – hTK Fyn SH2 domain - NMR<br /> | ||
- | **[[6edf]] - hTK Fyn residues 1-77<br /> | ||
- | **[[3uf4]] – mTK Fyn SH3-SH2 domain – mouse<br /> | ||
- | **[[3uf4]] - mTK Fyn SH2+SH3 domains<br /> | ||
- | **[[2l2p]], [[2lp5]] - cTK Fyn SH3 domain (mutant) - chicken - NMR<br /> | ||
- | |||
- | *Fyn complex | ||
- | |||
- | **[[1fyn]], [[4znx]] - hTK Fyn SH3 domain + peptide<br /> | ||
- | **[[1nyf]], [[1nyg]], [[1a0n]], [[1azg]] - hTK Fyn SH3 domain + peptide – NMR<br /> | ||
- | **[[5zau]] - hTK Fyn SH3 domain + monobody binder – NMR<br /> | ||
- | **[[1efn]], [[1avz]] - hTK Fyn SH3 domain + HIV Nef protein<br /> | ||
- | **[[4d8d]], [[7d7s]] - hTK Fyn SH3 domain (mutant) + HIV Nef protein<br /> | ||
- | **[[1m27]] - hTK Fyn SH3 domain + SH2 domain protein 1A + SLAM peptide<br /> | ||
- | **[[4d8d]], [[1efn]] - hTK Fyn SH3 domain (mutant) + HIV Nef protein<br /> | ||
- | **[[3ua7]] – hTK Fyn SH3 domain + hepatitis virus peptide<br /> | ||
- | **[[4eik]] - hTK Fyn SH3 domain + VSL12 peptide<br /> | ||
- | **[[4u1p]] - hTK Fyn SH2 domain + phosphopeptide<BR /> | ||
- | **[[1aot]], [[1aou]], [[2mrk]] - hTK Fyn SH2 domain + phosphopeptide - NMR<BR /> | ||
- | **[[2dq7]] – hTK kinase domain + staurosporine<br /> | ||
- | |||
- | *'''Hck tyrosine kinase''' Domains: SH3 81-137; SH2 119-224; SH1 or kinase+C-terminal 225-525; | ||
- | |||
- | **[[3hck]] - hTK Hck SH2 domain - NMR<BR /> | ||
- | **[[1bu1]] - hTK Hck SH3 domain <BR /> | ||
- | **[[4hck]], [[5hck]] - hTK Hck SH3 domain - NMR<BR /> | ||
- | **[[2oj2]], [[2oi3]] - hTK Hck SH3 domain + peptide - NMR<BR /> | ||
- | **[[3rbb]], [[3rea]], [[3reb]] - hTK Hck SH3 domain (mutant) + HIV NEF<BR /> | ||
- | **[[5nuh]] - hTK Hck SH3 domain + SIV NEF<BR /> | ||
- | **[[4orz]] - hTK Hck SH3 domain (mutant) + HIV NEF + single domain antibody<br /> | ||
- | **[[3nhn]] - hTK Hck SH3-SH2-linker domain <BR /> | ||
- | **[[4u5w]] - hTK Hck SH3-SH2 domains + NEF <br /> | ||
- | **[[2c0i]], [[2c0o]], [[2c0t]] - hTK Hck SH3-SH2-SH1 domain + inhibitor<BR /> | ||
- | **[[5h0b]], [[5h0e]], [[5h0g]], [[5h0h]] - hTK Hck SH3-SH2-SH1 domain (mutant) + inhibitor<BR /> | ||
- | **[[2hk5]], [[5zj6]] - hTK Hck kinase domain + inhibitor<BR /> | ||
- | **[[1qcf]], [[3vrz]], [[3vs0]], [[3vs3]], [[3vs4]], [[3vs5]], [[3vs6]], [[3vs7]] - hTK Hck SH3-SH2-kinase-C-terminal domain + inhibitor<BR /> | ||
- | **[[3vry]], [[3vs1]], [[3vs2]] - hTK Hck SH3-SH2-kinase-C-terminal domain (mutant) + inhibitor<BR /> | ||
- | **[[1ad5]] - hTK Hck SH3-SH2-kinase-C-terminal domain + AMPPNP<BR /> | ||
- | **[[2hck]] - hTK Hck SH3-SH2-kinase-C-terminal domain + quercetin<BR /> | ||
- | **[[4lud]], [[4lue]] - hTK Hck SH2+SH3+kinase+C-terrminal domain (mutant) + fluorescent compound<br /> | ||
- | |||
- | *'''Itk/Tsk tyrosine kinase''' or '''interleukin-2 tyrosine kinase'''; domains – SH2 236-344; SH3 160-236; kinase 357-620 | ||
- | |||
- | **[[2etz]], [[2eu0]] – hTK Itk SH2 domain + phosphopeptide – NMR<BR /> | ||
- | **[[2yuq]], [[2lmj]] – hTK Itk SH3 domain – NMR<BR /> | ||
- | **[[1sm2]], [[1snu]], [[1snx]] – hTK Itk kinase domain <BR /> | ||
- | **[[3miy]] – hTK Itk kinase domain + cancer drug<BR /> | ||
- | **[[3v5j]], [[3v5l]], [[3v8t]], [[3v8w]] – hTK Itk kinase domain + inhibitor<BR /> | ||
- | **[[3mj1]], [[3mj2]], [[3qgw]], [[3qgy]], [[4hct]], [[4hcu]], [[4hcv]], [[4kio]] – hTK Itk kinase domain (mutant) + inhibitor<BR /> | ||
- | **[[3t9t]] – hTK Itk kinase domain (mutant) + arthritis drug<BR /> | ||
- | **[[2e6i]] – hTK Itk BTK motif – NMR<BR /> | ||
- | **[[4l7s]], [[4m0y]], [[4m0z]], [[4m12]], [[4m13]], [[4m14]], [[4m15]], [[4mf0]], [[4mf1]], [[3v5j]], [[3v5l]], [[3v8t]], [[3v8w]] - hTK Itk kinase domain + inhibitor<br /> | ||
- | **[[4pp9]], [[4ppa]], [[4ppb]], [[4ppc]], [[4pqn]], [[4qd6]], [[4rfm]], [[4kio]] - hTK Itk kinase domain (mutant) + inhibitor<br /> | ||
- | **[[1lui]], [[1luk]], [[1lum]], [[1lun]] – mTK Itk SH2 domain – NMR<BR /> | ||
- | **[[3s9k]] – mTK Itk SH2 domain <BR /> | ||
- | **[[1awj]], [[2rn8]], [[2rna]] – mTK Itk SH3 domain – NMR<BR /> | ||
- | **[[2k79]], [[2k7a]] – mTK Itk SH2+SH3 domains – NMR<BR /> | ||
*'''Jak tyrosine kinase''' see [[Janus kinase]] | *'''Jak tyrosine kinase''' see [[Janus kinase]] | ||
- | |||
- | *'''Lymphocyte-specific tyrosine kinase Lck''' (Domains: SH3 58-118; SH2 122-225; kinase 230-500) | ||
- | |||
- | **[[1kik]], [[1h92]] - hTK Lck SH3 domain – NMR<BR /> | ||
- | **[[2iim]] - hTK Lck SH3 domain<br /> | ||
- | **[[4d8k]], [[1x27]] - hTK Lck SH3-SH2 domain<br /> | ||
- | **[[3lck]] - hTK Lck kinase domain<br /> | ||
- | |||
- | *Lck complex | ||
- | |||
- | **[[1lcj]], [[1lkk]], [[1lkl]] - hTK Lck SH2 domain (mutant) + phosphopeptide<br /> | ||
- | **[[1cwd]], [[1cwe]], [[1ijr]] - hTK Lck SH2 domain + phosphopeptide<br /> | ||
- | **[[1bhf]] - hTK Lck SH2 domain + peptide inhibitor<br /> | ||
- | **[[1fbz]] - hTK Lck SH2 domain + inhibitor<br /> | ||
- | **[[1bhh]] - hTK Lck SH2 domain + T-lymphocyte-specific TK<br /> | ||
- | **[[5mtm]], [[5mtn]] - hTK Lck SH2 domain + monobody<br /> | ||
- | **[[1lck]] - hTK Lck SH3-SH2 domain (mutant) + phosphopeptide<br /> | ||
- | **[[1x27]] - hTK Lck SH3-SH2 domain + peptide<br /> | ||
- | **[[1qpj]] - hTK Lck kinase domain + staurosporin<br /> | ||
- | **[[2of2]], [[2of4]], [[2ofu]], [[2ofv]], [[2og8]], [[3b2w]], [[3bym]], [[3bys]], [[3byu]], [[2zm1]], [[2zm4]], [[3byo]], [[2zyb]], [[3ac1]], [[3ac2]], [[3ac3]], [[3ac4]], [[3ac5]], [[3ac8]], [[3acj]], [[3ack]], [[3kmm]], [[3ad4]], [[3ad5]], [[3ad6]], [[1qpc]], [[1qpd]], [[1qpe]], [[6pdj]] - hTK Lck kinase domain + inhibitor<br /> | ||
- | **[[3mpm]] - hTK Lck kinase domain (mutant) + inhibitor<br /> | ||
- | **[[4c3f]] - hTK Lck kinase domain (mutant) + chemotype<br /> | ||
- | **[[2pl0]] - hTK Lck kinase domain + anti-cancer drug<br /> | ||
- | **[[3kxz]] - hTK Lck kinase domain + probe molecule<br /> | ||
- | **[[1q68]] - hTK Lck residues 6-34 (mutant) + CD4 peptide – NMR<br /> | ||
- | **[[1q69]] - hTK Lck residues 6-34 (mutant) + CD8 – NMR<br /> | ||
- | |||
- | *'''Lyn tyrosine kinase''' (Domains: SH3 39-101; SH2 115-229; kinase 239-512) | ||
- | |||
- | **[[4tzi]] - hTK Lyn SH2 domain <br /> | ||
- | **[[6nmw]] - hTK Lyn SH3 domain <br /> | ||
- | **[[1w1f]] - hTK Lyn SH3 domain – NMR<br /> | ||
- | **[[1wa7]] - hTK Lyn SH3 domain + peptide – NMR<br /> | ||
- | **[[3a4o]] - hTK Lyn residues 233-512 + staurosporine<br /> | ||
- | **[[5xy1]] - hTK Lyn kinase domain + inhibitor<br /> | ||
- | **[[2zv7]] - mTK Lyn kinase domain<br /> | ||
- | **[[2zv8]] - mTK Lyn kinase domain + AMPPNP<br /> | ||
- | **[[2zv9]] - mTK Lyn kinase domain + PP2<br /> | ||
- | **[[2zva]] - mTK Lyn kinase domain + cancer drug<br /> | ||
*'''p55-blk tyrosine kinase''' | *'''p55-blk tyrosine kinase''' | ||
**[[1blj]], [[1blk]] - mTK p55-blk SH2 domain – NMR<BR /> | **[[1blj]], [[1blk]] - mTK p55-blk SH2 domain – NMR<BR /> | ||
- | |||
- | *'''Ptk6 tyrosine kinase or breast tumor kinase Brk or tyrosine protein kinase 6''' | ||
- | |||
- | **[[1rja]] - hTK Ptk6 SH2 domain – NMR<br /> | ||
- | **[[2kgt]] - hTK Ptk6 SH3 domain – NMR<br /> | ||
- | **[[5d7v]], [[6cz2]] - hTK Ptk6 kinase domain <br /> | ||
- | **[[5da3]], [[6cz3]], [[6cz4]] - hTK Ptk6 kinase domain + inhibitor<br /> | ||
- | **[[5h2u]] - hTK Ptk6 kinase domain (mutant) + cancer drug<br /> | ||
- | |||
- | *'''Ptk7 tyrosine kinase''' | ||
- | |||
- | **[[6vg3]] - hTK Ptk7 kinase domain<br /> | ||
- | |||
- | *'''PtkA tyrosine kinase''' | ||
- | |||
- | **[[6f2x]] - TK PtkA – ''Mycobacterium tuberculosis'' - NMR<br /> | ||
- | |||
- | *'''Pyk2 tyrosine kinase or protein-tyrosine kinase 2-β (Domains: kinase 414-692; FAT 861-1009)''' | ||
- | |||
- | **[[3cc6]], [[3fzo]] - hTK Pyk2 kinase domain <br /> | ||
- | **[[3gm2]] - hTK Pyk2 FAT domain<br /> | ||
- | **[[3gm3]] - hTK Pyk2 FAT domain (mutant)<br /> | ||
- | **[[4eku]] – hTK Pyk2 FERM domain<br /> | ||
- | **[[2lk4]] - hTK Pyk2 FAT domain – NMR<br /> | ||
- | |||
- | *Pyk2 complex | ||
- | |||
- | **[[3fzp]] - hTK Pyk2 kinase domain + ATPγS<br /> | ||
- | **[[3fzr]], [[3fzs]], [[3fzt]], [[3h3c]], [[3et7]], [[5to8]], [[5tob]], [[4h1j]], [[4h1m]] - hTK Pyk2 kinase domain + inhibitor<br /> | ||
- | **[[3gm1]], [[4r32]] - hTK Pyk2 FAT domain + paxillin peptide<br /> | ||
- | **[[4xek]], [[4xev]], [[4xef]] - hTK Pyk2 FAT domain + leupaxin peptide<br /> | ||
- | **[[4h1j]] - hFAK2 kinase domain + pyrazole inhibitor<br /> | ||
- | **[[3h3c]] - hFAK2 kinase domain + pyrimidine inhibitor<br /> | ||
- | **[[4h1m]] - hFAK2 kinase domain + indole inhibitor<br /> | ||
- | **[[3u3f]] – hFAK2 FAT domain (mutant) + paxillin LD2 motif<br /> | ||
- | |||
- | *'''Ros tyrosine kinase''' | ||
- | |||
- | **[[3zbf]] - hTK Ros kinase domain + cancer drug<br /> | ||
- | **[[4uxl]] - hTK Ros kinase domain + inhibitor<br /> | ||
* '''Src tyrosine kinase''' or '''proto-oncogene tyrosine protein kinase''' (Domains: SH3 85-140; SH2 140-251; kinase 253-535) | * '''Src tyrosine kinase''' or '''proto-oncogene tyrosine protein kinase''' (Domains: SH3 85-140; SH2 140-251; kinase 253-535) | ||
Line 359: | Line 213: | ||
**[[2h8h]] – hTK + inhibitor<br /> | **[[2h8h]] – hTK + inhibitor<br /> | ||
+ | |||
+ | *'''Lymphocyte-specific tyrosine kinase Lck''' (Domains: SH3 58-118; SH2 122-225; kinase 230-500) | ||
+ | |||
+ | **[[1kik]], [[1h92]] - hTK Lck SH3 domain – NMR<BR /> | ||
+ | **[[2iim]] - hTK Lck SH3 domain<br /> | ||
+ | **[[4d8k]], [[1x27]] - hTK Lck SH3-SH2 domain<br /> | ||
+ | **[[3lck]] - hTK Lck kinase domain<br /> | ||
+ | |||
+ | *Lck complex | ||
+ | |||
+ | **[[1lcj]], [[1lkk]], [[1lkl]] - hTK Lck SH2 domain (mutant) + phosphopeptide<br /> | ||
+ | **[[1cwd]], [[1cwe]], [[1ijr]] - hTK Lck SH2 domain + phosphopeptide<br /> | ||
+ | **[[1bhf]] - hTK Lck SH2 domain + peptide inhibitor<br /> | ||
+ | **[[1fbz]] - hTK Lck SH2 domain + inhibitor<br /> | ||
+ | **[[1bhh]] - hTK Lck SH2 domain + T-lymphocyte-specific TK<br /> | ||
+ | **[[5mtm]], [[5mtn]] - hTK Lck SH2 domain + monobody<br /> | ||
+ | **[[1lck]] - hTK Lck SH3-SH2 domain (mutant) + phosphopeptide<br /> | ||
+ | **[[1x27]] - hTK Lck SH3-SH2 domain + peptide<br /> | ||
+ | **[[1qpj]] - hTK Lck kinase domain + staurosporin<br /> | ||
+ | **[[2of2]], [[2of4]], [[2ofu]], [[2ofv]], [[2og8]], [[3b2w]], [[3bym]], [[3bys]], [[3byu]], [[2zm1]], [[2zm4]], [[3byo]], [[2zyb]], [[3ac1]], [[3ac2]], [[3ac3]], [[3ac4]], [[3ac5]], [[3ac8]], [[3acj]], [[3ack]], [[3kmm]], [[3ad4]], [[3ad5]], [[3ad6]], [[1qpc]], [[1qpd]], [[1qpe]], [[6pdj]] - hTK Lck kinase domain + inhibitor<br /> | ||
+ | **[[3mpm]] - hTK Lck kinase domain (mutant) + inhibitor<br /> | ||
+ | **[[4c3f]] - hTK Lck kinase domain (mutant) + chemotype<br /> | ||
+ | **[[2pl0]] - hTK Lck kinase domain + anti-cancer drug<br /> | ||
+ | **[[3kxz]] - hTK Lck kinase domain + probe molecule<br /> | ||
+ | **[[1q68]] - hTK Lck residues 6-34 (mutant) + CD4 peptide – NMR<br /> | ||
+ | **[[1q69]] - hTK Lck residues 6-34 (mutant) + CD8 – NMR<br /> | ||
*'''Syk - spleen tyrosine kinase''' | *'''Syk - spleen tyrosine kinase''' | ||
Line 374: | Line 254: | ||
**[[4fl3]] - hSyk kinase domain (mutant) + ANP<br /> | **[[4fl3]] - hSyk kinase domain (mutant) + ANP<br /> | ||
**[[1a81]] – hSyk tandem SH2 domain + T-cell surface peptide <br /> | **[[1a81]] – hSyk tandem SH2 domain + T-cell surface peptide <br /> | ||
+ | |||
+ | *'''Itk/Tsk tyrosine kinase''' or '''interleukin-2 tyrosine kinase'''; domains – SH2 236-344; SH3 160-236; kinase 357-620 | ||
+ | |||
+ | **[[2etz]], [[2eu0]] – hTK Itk SH2 domain + phosphopeptide – NMR<BR /> | ||
+ | **[[2yuq]], [[2lmj]] – hTK Itk SH3 domain – NMR<BR /> | ||
+ | **[[1sm2]], [[1snu]], [[1snx]] – hTK Itk kinase domain <BR /> | ||
+ | **[[3miy]] – hTK Itk kinase domain + cancer drug<BR /> | ||
+ | **[[3v5j]], [[3v5l]], [[3v8t]], [[3v8w]] – hTK Itk kinase domain + inhibitor<BR /> | ||
+ | **[[3mj1]], [[3mj2]], [[3qgw]], [[3qgy]], [[4hct]], [[4hcu]], [[4hcv]], [[4kio]] – hTK Itk kinase domain (mutant) + inhibitor<BR /> | ||
+ | **[[3t9t]] – hTK Itk kinase domain (mutant) + arthritis drug<BR /> | ||
+ | **[[2e6i]] – hTK Itk BTK motif – NMR<BR /> | ||
+ | **[[4l7s]], [[4m0y]], [[4m0z]], [[4m12]], [[4m13]], [[4m14]], [[4m15]], [[4mf0]], [[4mf1]], [[3v5j]], [[3v5l]], [[3v8t]], [[3v8w]] - hTK Itk kinase domain + inhibitor<br /> | ||
+ | **[[4pp9]], [[4ppa]], [[4ppb]], [[4ppc]], [[4pqn]], [[4qd6]], [[4rfm]], [[4kio]] - hTK Itk kinase domain (mutant) + inhibitor<br /> | ||
+ | **[[1lui]], [[1luk]], [[1lum]], [[1lun]] – mTK Itk SH2 domain – NMR<BR /> | ||
+ | **[[3s9k]] – mTK Itk SH2 domain <BR /> | ||
+ | **[[1awj]], [[2rn8]], [[2rna]] – mTK Itk SH3 domain – NMR<BR /> | ||
+ | **[[2k79]], [[2k7a]] – mTK Itk SH2+SH3 domains – NMR<BR /> | ||
+ | |||
+ | *'''Zap-70 tyrosine kinase''' (Domains: SH2 1-259; kinase 327-606 | ||
+ | |||
+ | **[[4k2r]] – hTK Zap-70<br /> | ||
+ | **[[2ozo]] - hTK Zap-70 (mutant) <br /> | ||
+ | **[[1m61]] - hTK Zap-70 SH2 domain | ||
+ | |||
+ | *Zap-70 complex | ||
+ | |||
+ | **[[2oq1]], [[4xz1]] - hTK Zap-70 SH2 domain + peptide<br /> | ||
+ | **[[4xz0]] - hTK Zap-70 SH2 domain + inhibitor<br /> | ||
+ | **[[1u59]] - hTK Zap-70 kinase domain + staurosporine | ||
+ | |||
+ | *'''Pyk2 tyrosine kinase or protein-tyrosine kinase 2-β (Domains: kinase 414-692; FAT 861-1009)''' | ||
+ | |||
+ | **[[3cc6]], [[3fzo]] - hTK Pyk2 kinase domain <br /> | ||
+ | **[[3gm2]] - hTK Pyk2 FAT domain<br /> | ||
+ | **[[3gm3]] - hTK Pyk2 FAT domain (mutant)<br /> | ||
+ | **[[4eku]] – hTK Pyk2 FERM domain<br /> | ||
+ | **[[2lk4]] - hTK Pyk2 FAT domain – NMR<br /> | ||
+ | |||
+ | *Pyk2 complex | ||
+ | |||
+ | **[[3fzp]] - hTK Pyk2 kinase domain + ATPγS<br /> | ||
+ | **[[3fzr]], [[3fzs]], [[3fzt]], [[3h3c]], [[3et7]], [[5to8]], [[5tob]], [[4h1j]], [[4h1m]] - hTK Pyk2 kinase domain + inhibitor<br /> | ||
+ | **[[3gm1]], [[4r32]] - hTK Pyk2 FAT domain + paxillin peptide<br /> | ||
+ | **[[4xek]], [[4xev]], [[4xef]] - hTK Pyk2 FAT domain + leupaxin peptide<br /> | ||
+ | **[[4h1j]] - hFAK2 kinase domain + pyrazole inhibitor<br /> | ||
+ | **[[3h3c]] - hFAK2 kinase domain + pyrimidine inhibitor<br /> | ||
+ | **[[4h1m]] - hFAK2 kinase domain + indole inhibitor<br /> | ||
+ | **[[3u3f]] – hFAK2 FAT domain (mutant) + paxillin LD2 motif<br /> | ||
+ | |||
+ | *'''CapAB tyrosine kinase''' | ||
+ | |||
+ | **[[3bfv]] - SaTK CapA1/CapB2 – ''Staphylococcus aureus'' <br /> | ||
+ | **[[2ved]] - SaTK CapA1/CapB2 + Mg + ADP | ||
+ | |||
+ | *'''Fer tyrosine kinase''' | ||
+ | |||
+ | **[[2kk6]] - hTK Fer SH2 domain – NMR<BR /> | ||
+ | **[[6kc4]] - hTK Fer SH2 domain + phosphopeptide<BR /> | ||
+ | |||
+ | *'''Ptk6 tyrosine kinase or breast tumor kinase Brk or tyrosine protein kinase 6''' | ||
+ | |||
+ | **[[1rja]] - hTK Ptk6 SH2 domain – NMR<br /> | ||
+ | **[[2kgt]] - hTK Ptk6 SH3 domain – NMR<br /> | ||
+ | **[[5d7v]], [[6cz2]] - hTK Ptk6 kinase domain <br /> | ||
+ | **[[5da3]], [[6cz3]], [[6cz4]] - hTK Ptk6 kinase domain + inhibitor<br /> | ||
+ | **[[5h2u]] - hTK Ptk6 kinase domain (mutant) + cancer drug<br /> | ||
+ | |||
+ | *'''Ptk7 tyrosine kinase''' | ||
+ | |||
+ | **[[6vg3]] - hTK Ptk7 kinase domain<br /> | ||
+ | |||
+ | *'''PtkA tyrosine kinase''' | ||
+ | |||
+ | **[[6f2x]] - TK PtkA – ''Mycobacterium tuberculosis'' - NMR<br /> | ||
+ | |||
+ | *'''Lyn tyrosine kinase''' (Domains: SH3 39-101; SH2 115-229; kinase 239-512) | ||
+ | |||
+ | **[[4tzi]] - hTK Lyn SH2 domain <br /> | ||
+ | **[[6nmw]] - hTK Lyn SH3 domain <br /> | ||
+ | **[[1w1f]] - hTK Lyn SH3 domain – NMR<br /> | ||
+ | **[[1wa7]] - hTK Lyn SH3 domain + peptide – NMR<br /> | ||
+ | **[[3a4o]] - hTK Lyn residues 233-512 + staurosporine<br /> | ||
+ | **[[5xy1]] - hTK Lyn kinase domain + inhibitor<br /> | ||
+ | **[[2zv7]] - mTK Lyn kinase domain<br /> | ||
+ | **[[2zv8]] - mTK Lyn kinase domain + AMPPNP<br /> | ||
+ | **[[2zv9]] - mTK Lyn kinase domain + PP2<br /> | ||
+ | **[[2zva]] - mTK Lyn kinase domain + cancer drug<br /> | ||
+ | |||
+ | *'''Txk tyrosine kinase''' | ||
+ | |||
+ | **[[2dm0]] - hTK Txk SH2 domain – NMR<br /> | ||
+ | |||
+ | *'''Yes tyrosine kinase''' | ||
+ | |||
+ | **[[2hda]] - hTK Yes SH3 domain <br /> | ||
+ | **[[5mtj]] - hTK Yes SH2 domain + monobody<br /> | ||
*'''Tec tyrosine kinase''' | *'''Tec tyrosine kinase''' | ||
Line 380: | Line 356: | ||
**[[1gl5]] - hTK Tec SH3 domain - NMR<br /> | **[[1gl5]] - hTK Tec SH3 domain - NMR<br /> | ||
- | *''' | + | *'''Fes/Fps tyrosine kinase''' |
- | **[[ | + | **[[1wqu]], [[2dcr]] - hTK Fes SH2 domain - NMR<br /> |
+ | **[[3bkb]] - hTK Fes SH2+kinase domain - NMR<br /> | ||
+ | **[[4dyl]] - hTK Fes F-Bar domain <br /> | ||
+ | **[[3cbl]] - hTK Fes SH2+kinase domain + peptide<br /> | ||
+ | **[[3cd3]] - hTK Fes SH2+kinase domain + peptide + staurosporine<br /> | ||
+ | **[[4e93]], [[6jmf]] - hTK TFes + inhibitor<br /> | ||
+ | |||
+ | *'''Etk tyrosine kinase''' | ||
+ | |||
+ | **[[3cio]] - EcTK Etk kinase domain – ''Escherichia coli''<br /> | ||
+ | |||
+ | *'''Wzc tyrosine kinase''' | ||
+ | |||
+ | **[[3la6]] - EcTK Wzc kinase domain <br /> | ||
+ | |||
+ | *'''Ros tyrosine kinase''' | ||
+ | |||
+ | **[[3zbf]] - hTK Ros kinase domain + cancer drug<br /> | ||
+ | **[[4uxl]] - hTK Ros kinase domain + inhibitor<br /> | ||
*'''Tyk2 tyrosine kinase''' (Domains: SH2+FERM 23-540; pseudokinase 541-880; kinase 880-1170) | *'''Tyk2 tyrosine kinase''' (Domains: SH2+FERM 23-540; pseudokinase 541-880; kinase 880-1170) | ||
Line 395: | Line 389: | ||
**[[4po6]] - hTK Tyk2 SH2+FERM domains + IFNAR1 peptide<br /> | **[[4po6]] - hTK Tyk2 SH2+FERM domains + IFNAR1 peptide<br /> | ||
- | *''' | + | *'''Hck tyrosine kinase''' Domains: SH3 81-137; SH2 119-224; SH1 or kinase+C-terminal 225-525; |
- | **[[ | + | **[[3hck]] - hTK Hck SH2 domain - NMR<BR /> |
+ | **[[1bu1]] - hTK Hck SH3 domain <BR /> | ||
+ | **[[4hck]], [[5hck]] - hTK Hck SH3 domain - NMR<BR /> | ||
+ | **[[2oj2]], [[2oi3]] - hTK Hck SH3 domain + peptide - NMR<BR /> | ||
+ | **[[3rbb]], [[3rea]], [[3reb]] - hTK Hck SH3 domain (mutant) + HIV NEF<BR /> | ||
+ | **[[5nuh]] - hTK Hck SH3 domain + SIV NEF<BR /> | ||
+ | **[[4orz]] - hTK Hck SH3 domain (mutant) + HIV NEF + single domain antibody<br /> | ||
+ | **[[3nhn]] - hTK Hck SH3-SH2-linker domain <BR /> | ||
+ | **[[4u5w]] - hTK Hck SH3-SH2 domains + NEF <br /> | ||
+ | **[[2c0i]], [[2c0o]], [[2c0t]] - hTK Hck SH3-SH2-SH1 domain + inhibitor<BR /> | ||
+ | **[[5h0b]], [[5h0e]], [[5h0g]], [[5h0h]] - hTK Hck SH3-SH2-SH1 domain (mutant) + inhibitor<BR /> | ||
+ | **[[2hk5]], [[5zj6]] - hTK Hck kinase domain + inhibitor<BR /> | ||
+ | **[[1qcf]], [[3vrz]], [[3vs0]], [[3vs3]], [[3vs4]], [[3vs5]], [[3vs6]], [[3vs7]] - hTK Hck SH3-SH2-kinase-C-terminal domain + inhibitor<BR /> | ||
+ | **[[3vry]], [[3vs1]], [[3vs2]] - hTK Hck SH3-SH2-kinase-C-terminal domain (mutant) + inhibitor<BR /> | ||
+ | **[[1ad5]] - hTK Hck SH3-SH2-kinase-C-terminal domain + AMPPNP<BR /> | ||
+ | **[[2hck]] - hTK Hck SH3-SH2-kinase-C-terminal domain + quercetin<BR /> | ||
+ | **[[4lud]], [[4lue]] - hTK Hck SH2+SH3+kinase+C-terrminal domain (mutant) + fluorescent compound<br /> | ||
- | *''' | + | *'''Ack1 tyrosine kinase''' or '''activated cdc42 kinase 1''' |
- | **[[ | + | **[[1u46]], [[4hzr]] - hTK Ack1 kinase domain <br /> |
- | + | **[[4hzs]] - hTK Ack1 kinase+SH3 domains <br /> | |
- | + | **[[1u54]] - hTK Ack1 kinase domain + AMPPCP <br /> | |
- | + | **[[1u4d]], [[3eqp]], [[3eqr]], [[4ewh]], [[4id7]], [[5zxb]] - hTK Ack1 kinase domain + inhibitor<br /> | |
- | + | ||
- | **[[ | + | |
- | **[[ | + | |
- | **[[ | + | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
*'''RECEPTOR TYROSINE KINASES - RTK''' | *'''RECEPTOR TYROSINE KINASES - RTK''' | ||
- | |||
- | *'''Bone marrow tyrosine kinase'''; Domains – kinase 411-675 | ||
- | |||
- | **[[2ekx]] - hTK Bmx SH2 domain – NMR<BR /> | ||
- | **[[2ys2]] - hTK Bmx Btk motif – NMR<BR /> | ||
- | |||
- | *Bone marrow tyrosine kinase complex | ||
- | |||
- | **[[3sxr]] - hTK Bmx kinase domain (mutant) + anti-cancer drug<br /> | ||
- | **[[3sxs]], [[6i99]] - hTK Bmx kinase domain (mutant) + inhibitor<br /> | ||
*'''Bruton’s tyrosine kinase Btk''' (Domains: PH 1-170; SH3 216-273; SH2 273-378; kinase 378-659) | *'''Bruton’s tyrosine kinase Btk''' (Domains: PH 1-170; SH3 216-273; SH2 273-378; kinase 378-659) | ||
Line 454: | Line 443: | ||
**[[4y94]] - bTK Btk kinase domain + inhibitor<br /> | **[[4y94]] - bTK Btk kinase domain + inhibitor<br /> | ||
**[[6mny]] - mTK Btk kinase domain + inhibitor<br /> | **[[6mny]] - mTK Btk kinase domain + inhibitor<br /> | ||
- | |||
- | *'''Cbl-c tyrosine kinase''' or '''signal transduction protein Cbl-c''' | ||
- | |||
- | **[[3vrn]] - hTK Cbl-c kinase domain <br /> | ||
- | **[[3vrq]] - hTK Cbl-c kinase domain (mutant)<br /> | ||
- | **[[3vro]] - hTK Cbl-c kinase domain + Src peptide<br /> | ||
- | **[[3vrp]] - hTK Cbl-c kinase domain + EGRF peptide<br /> | ||
- | **[[3vrr]] - hTK Cbl-c kinase domain (mutant) + EGRF peptide<br /> | ||
- | **[[3op0]] - hTK Cbl-c N-terminal domain (mutant) + EGRF peptide<br /> | ||
*'''c-FMS tyrosine kinase or macrophage colony-stimulating factor 1 receptor''' see [[Colony-stimulating factor receptor]] | *'''c-FMS tyrosine kinase or macrophage colony-stimulating factor 1 receptor''' see [[Colony-stimulating factor receptor]] | ||
*'''DDR1 and DDR2 tyrosine kinase receptors''' see [[Epithelial discoidin domain-containing receptor]] | *'''DDR1 and DDR2 tyrosine kinase receptors''' see [[Epithelial discoidin domain-containing receptor]] | ||
- | |||
- | *'''ErbB tyrosine kinase''' see [[Epidermal Growth Factor Receptor]] | ||
- | |||
- | *'''Flt3 tyrosine kinase'''; Domains - kinase 564-958 | ||
- | |||
- | **[[1rjb]] - hTK Flt3 kinase domain <br /> | ||
- | **[[4rt7]], [[6il3]], [[5x02]] - hTK Flt3 kinase domain + inhibitor<br /> | ||
- | **[[4xuf]], [[6jqr]] - hTK Flt3 kinase domain (mutant) + leukemia drug<br /> | ||
- | **[[3qs9]], [[3qs7]] - hTK Flt3 residues 27-540 + SL cytokine <br /> | ||
*'''Kit tyrosine kinase''' or '''mast/stem cell growth factor receptor Kit'''; Domains – extracellular 1-519; kinase 547-693, 754-935 | *'''Kit tyrosine kinase''' or '''mast/stem cell growth factor receptor Kit'''; Domains – extracellular 1-519; kinase 547-693, 754-935 | ||
Line 488: | Line 459: | ||
**[[2o26]] - hTK Kit residues 25-314 + Kit ligand<br /> | **[[2o26]] - hTK Kit residues 25-314 + Kit ligand<br /> | ||
**[[4k94]], [[4k9e]] - hTK Kit residues 308-518 + antibody<br /> | **[[4k94]], [[4k9e]] - hTK Kit residues 308-518 + antibody<br /> | ||
- | |||
- | *'''Matk tyrosine kinase''' or '''megakaryocyte-associated tyrosine-protein kinase''' | ||
- | |||
- | **[[3us4]] - hTK Matk SH2 domain <br /> | ||
*'''Mer tyrosine kinase (Domains: FN3 373-483; kinase 570-864)''' | *'''Mer tyrosine kinase (Domains: FN3 373-483; kinase 570-864)''' | ||
Line 508: | Line 475: | ||
**[[7aay]] - hTK Mer kinase domain (mutant) + anti-cancer drug<br /> | **[[7aay]] - hTK Mer kinase domain (mutant) + anti-cancer drug<br /> | ||
- | *''' | + | *'''Bone marrow tyrosine kinase'''; Domains – kinase 411-675 |
+ | |||
+ | **[[2ekx]] - hTK Bmx SH2 domain – NMR<BR /> | ||
+ | **[[2ys2]] - hTK Bmx Btk motif – NMR<BR /> | ||
+ | |||
+ | *Bone marrow tyrosine kinase complex | ||
+ | |||
+ | **[[3sxr]] - hTK Bmx kinase domain (mutant) + anti-cancer drug<br /> | ||
+ | **[[3sxs]], [[6i99]] - hTK Bmx kinase domain (mutant) + inhibitor<br /> | ||
+ | |||
+ | *'''ErbB tyrosine kinase''' see [[Epidermal Growth Factor Receptor]] | ||
*'''MuSK tyrosine kinase''' or '''muscle skeleton receptor tyrosine kinase''' | *'''MuSK tyrosine kinase''' or '''muscle skeleton receptor tyrosine kinase''' | ||
Line 514: | Line 491: | ||
**[[3hkl]] - rTK MuSK Fz-Crd domain <br /> | **[[3hkl]] - rTK MuSK Fz-Crd domain <br /> | ||
**[[1luf]], [[2iep]] - rTK MuSK cytoplasmic domain <br /> | **[[1luf]], [[2iep]] - rTK MuSK cytoplasmic domain <br /> | ||
+ | |||
+ | *'''Sgk223 tyrosine kinase or sugen kinase''' | ||
+ | |||
+ | **[[5ve6]] - hTK <br /> | ||
+ | |||
+ | *'''Matk tyrosine kinase''' or '''megakaryocyte-associated tyrosine-protein kinase''' | ||
+ | |||
+ | **[[3us4]] - hTK Matk SH2 domain <br /> | ||
+ | |||
+ | *'''Cbl-c tyrosine kinase''' or '''signal transduction protein Cbl-c''' | ||
+ | |||
+ | **[[3vrn]] - hTK Cbl-c kinase domain <br /> | ||
+ | **[[3vrq]] - hTK Cbl-c kinase domain (mutant)<br /> | ||
+ | **[[3vro]] - hTK Cbl-c kinase domain + Src peptide<br /> | ||
+ | **[[3vrp]] - hTK Cbl-c kinase domain + EGRF peptide<br /> | ||
+ | **[[3vrr]] - hTK Cbl-c kinase domain (mutant) + EGRF peptide<br /> | ||
+ | **[[3op0]] - hTK Cbl-c N-terminal domain (mutant) + EGRF peptide<br /> | ||
+ | |||
+ | *'''Flt3 tyrosine kinase'''; Domains - kinase 564-958 | ||
+ | |||
+ | **[[1rjb]] - hTK Flt3 kinase domain <br /> | ||
+ | **[[4rt7]], [[6il3]], [[5x02]] - hTK Flt3 kinase domain + inhibitor<br /> | ||
+ | **[[4xuf]], [[6jqr]] - hTK Flt3 kinase domain (mutant) + leukemia drug<br /> | ||
+ | **[[3qs9]], [[3qs7]] - hTK Flt3 residues 27-540 + SL cytokine <br /> | ||
+ | |||
+ | *'''Tie2 tyrosine kinase''' | ||
+ | |||
+ | **[[1fvr]] - hTK Tie2 kinase domain <br /> | ||
*'''Ret tyrosine kinase''' or '''proto-oncogene tyrosine protein kinase receptor Ret''' | *'''Ret tyrosine kinase''' or '''proto-oncogene tyrosine protein kinase receptor Ret''' | ||
Line 540: | Line 545: | ||
**[[6osv]], [[6osh]] - hTK ROR2 Kringle domain + antibody<br /> | **[[6osv]], [[6osh]] - hTK ROR2 Kringle domain + antibody<br /> | ||
- | *''' | + | *'''c-Met tyrosine kinase''' see [[Hepatocyte growth factor receptor]] |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
}} | }} | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |
Revision as of 09:25, 30 December 2020
3D structures of tyrosine kinase
Updated on 30-December-2020 - For a general description of the protein see Tyrosine kinase